DK3600315T3 - Ny terapeutisk anvendelse af H3-ligander - Google Patents

Ny terapeutisk anvendelse af H3-ligander Download PDF

Info

Publication number
DK3600315T3
DK3600315T3 DK18714194.0T DK18714194T DK3600315T3 DK 3600315 T3 DK3600315 T3 DK 3600315T3 DK 18714194 T DK18714194 T DK 18714194T DK 3600315 T3 DK3600315 T3 DK 3600315T3
Authority
DK
Denmark
Prior art keywords
ligands
therapeutic use
new therapeutic
new
therapeutic
Prior art date
Application number
DK18714194.0T
Other languages
English (en)
Inventor
Jeanne-Marie Lecomte
Jean-Charles Schwartz
Olivier Labeeuw
Marc Capet
Original Assignee
Bioprojet Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Pharma filed Critical Bioprojet Pharma
Application granted granted Critical
Publication of DK3600315T3 publication Critical patent/DK3600315T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK18714194.0T 2017-03-21 2018-03-21 Ny terapeutisk anvendelse af H3-ligander DK3600315T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305309.1A EP3378477A1 (en) 2017-03-21 2017-03-21 New therapeutical use of h3-ligands
PCT/EP2018/057215 WO2018172432A1 (en) 2017-03-21 2018-03-21 New therapeutical use of h3-ligands

Publications (1)

Publication Number Publication Date
DK3600315T3 true DK3600315T3 (da) 2023-12-11

Family

ID=58464477

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18714194.0T DK3600315T3 (da) 2017-03-21 2018-03-21 Ny terapeutisk anvendelse af H3-ligander

Country Status (25)

Country Link
US (1) US11179329B2 (da)
EP (2) EP3378477A1 (da)
JP (2) JP7634987B2 (da)
KR (1) KR20190125354A (da)
CN (1) CN110891570A (da)
AU (1) AU2018238411B2 (da)
BR (1) BR112019019633A2 (da)
CA (1) CA3056710A1 (da)
DK (1) DK3600315T3 (da)
ES (1) ES2971063T3 (da)
FI (1) FI3600315T3 (da)
HR (1) HRP20231568T1 (da)
HU (1) HUE064403T2 (da)
IL (1) IL269424B2 (da)
LT (1) LT3600315T (da)
MA (1) MA48983A (da)
MX (1) MX388589B (da)
PL (1) PL3600315T3 (da)
PT (1) PT3600315T (da)
RS (1) RS64910B1 (da)
RU (1) RU2757996C2 (da)
SI (1) SI3600315T1 (da)
SM (1) SMT202300460T1 (da)
WO (1) WO2018172432A1 (da)
ZA (1) ZA201906238B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3378858A1 (en) * 2017-03-21 2018-09-26 Bioprojet Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same
PT3598975T (pt) 2018-07-27 2020-12-21 Bioprojet Soc Civ Novas combinações de um antagonista h3 e um inibidor da re-assimilação da noradrenalina, e suas utilizações terapêuticas
WO2020092604A1 (en) * 2018-10-30 2020-05-07 Concert Pharmaceuticals, Inc. Deuterated pitolisant
EP3976600B1 (en) * 2019-06-03 2026-05-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Non-hygroscopic crystalline salts of a pyrazole compound, pharmaceutical compositions containing them and their use
CN116675654B (zh) * 2022-02-22 2025-06-13 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途
CN122374013A (zh) * 2023-10-16 2026-07-10 生物计划制药公司 替洛利生的新制剂和使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2660862B1 (fr) * 1990-04-13 1994-09-23 Bioprojet Soc Civ Application therapeutique de derives de l'histamine, nouveau derive de l'histamine et utilisation de ces derives pour la preparation de medicaments.
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
MXPA04009961A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
JP5005351B2 (ja) 2003-12-11 2012-08-22 アボット・ラボラトリーズ Hivプロテアーゼ阻害性化合物
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
WO2009030716A1 (en) * 2007-09-06 2009-03-12 Glaxo Group Limited Piperazine derivative having affinity for the histamine h3 receptor
WO2009154562A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity
ME02320B (me) * 2010-09-02 2016-06-20 Suven Life Sciences Ltd Heterociklička jedinjenja kao ligandi histamin h3 receptora
US9212180B2 (en) * 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
EP3378858A1 (en) 2017-03-21 2018-09-26 Bioprojet Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same

Also Published As

Publication number Publication date
AU2018238411B2 (en) 2023-07-06
RU2757996C2 (ru) 2021-10-25
MX388589B (es) 2025-03-20
RS64910B1 (sr) 2023-12-29
HRP20231568T1 (hr) 2024-03-15
AU2018238411A1 (en) 2019-10-10
FI3600315T3 (fi) 2023-12-11
PL3600315T3 (pl) 2024-03-18
JP7634987B2 (ja) 2025-02-25
IL269424B1 (en) 2023-03-01
ZA201906238B (en) 2020-09-30
EP3378477A1 (en) 2018-09-26
SI3600315T1 (sl) 2024-02-29
HUE064403T2 (hu) 2024-03-28
EP3600315A1 (en) 2020-02-05
MA48983A (fr) 2021-04-21
NZ757456A (en) 2026-02-27
LT3600315T (lt) 2023-12-27
WO2018172432A1 (en) 2018-09-27
MX2019011183A (es) 2020-02-05
SMT202300460T1 (it) 2024-01-10
JP2020511551A (ja) 2020-04-16
IL269424B2 (en) 2023-07-01
ES2971063T3 (es) 2024-06-03
US11179329B2 (en) 2021-11-23
RU2019129447A (ru) 2021-03-18
CN110891570A (zh) 2020-03-17
IL269424A (en) 2019-11-28
KR20190125354A (ko) 2019-11-06
BR112019019633A2 (pt) 2020-04-14
CA3056710A1 (en) 2018-09-27
JP2023001210A (ja) 2023-01-04
RU2019129447A3 (da) 2021-03-18
PT3600315T (pt) 2023-12-11
US20200093738A1 (en) 2020-03-26
EP3600315B1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
LT3728870T (lt) Plokščių rinkinys
EP3487523A4 (en) THERAPEUTIC APPLICATIONS OF THE CPF1-BASED GENOME EDITION
PL4393545T3 (pl) Nowe zastosowania pochodnych piperydynylo-indolowych
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3259253T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
IL272851A (en) Methods of using dipivefrin
IL269540A (en) Purification of phycobiliproteins
IL268731A (en) New uses of anti-sirpg antibodies
DK3622953T3 (da) Kombinationsbehandling af cancer
DK3649781T3 (da) Forbedring af tvungen grænseopdeling
DK3569166T3 (da) Indretning til akut behandling af hjertestop
DK3166628T3 (da) Terapeutisk anvendelse af knoglemorfogenetiske proteiner
DK3307267T3 (da) Behandling af multipel sklerose
LT3600315T (lt) Naujas terapinis h3 ligandų panaudojimas
EP3849664C0 (en) PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
EP3347334A4 (en) DEHYDROHALOGENICATION OF FLUOROCHOLE HYDROGEN
DK3532076T3 (da) Immunterapeutiske behandlinger af tumorer
EP3752001A4 (en) DERIVATIVES OF SOBETIROM
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3390422T3 (da) Krystalformer af lnt
DK3363148T3 (da) Afdækning af krypteringsanvendelse
DK3529236T3 (da) Krystalformer af eravacyclin